Treatment policy for psoriasis and eczema: A survey among dermatologists in the Netherlands and Belgian Flanders

European Journal of Dermatology

Volumn 17, Issue 5, 2007, Pages 416-421

  Roelofzen, Judith H J ^a   Aben, Katja K H ^a,b   Khawar, Ali J M ^a   Van De Kerkhof, Peter C M ^a   Kiemeney, Lambertus A L M ^a,b   Van Der Valk, Pieter G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Oost   (Netherlands)

Author keywords

Coal tar; Eczema; Psoriasis; PUVA; Topical corticosteroids; Treatment

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; COAL TAR; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; FUMARIC ACID; METHOTREXATE; PIMECROLIMUS; PROTROPIC; RETINOID; TACROLIMUS; TAR; UNCLASSIFIED DRUG;

ARTICLE; BELGIUM; CONTROLLED STUDY; ECZEMA; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PHOTOTHERAPY; PSORIASIS; PUVA; QUESTIONNAIRE; ULTRAVIOLET B RADIATION;

BELGIUM; CARCINOGENS; COAL TAR; DERMATOLOGIC AGENTS; DERMATOLOGY; DRUG ADMINISTRATION ROUTES; ECZEMA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NETHERLANDS; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; PROFESSIONAL PRACTICE; PSORIASIS; QUESTIONNAIRES;

EID: 34548719840     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2007.0240     Document Type: Article

References (33)

1. Boffetta P, Jourenkova N, Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997; 8: 444-72.
2. Donato F, Monarca S, Marchionna G, et al. Mortality from cancer and chronic respiratory diseases among workers who manufacture carbon electrodes. Occup Environ Med 2000; 57: 484-7.
3. International Agency for Research on Cancer. Coal-tars and derived product. Polynuclear Aromatic Compounds, part 4, Bitumens, Coal-tars and Derived Products, Shale-oils and Soots. IARC Monogr Eval Carcinog Risk Chem Hum 1985; 35: 83-159.
4. Partanen T, Boffetta P. Cancer risk in asphalt workers and roofers: review and meta-analysis of epidemiologic studies. Am J Ind Med 1994; 26: 721-40.
5. Tsai PJ, Shieh HY, Lee WJ, et al. Health-risk assessment for workers exposed to polycyclic aromatic hydrocarbons (PAHs) in a carbon black manufacturing industry. Sci Total Environ 2001; 278: 137-50.
6. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1980; 1: 732-5.
7. Hannuksela-Svahn A, Pukkala E, Laara E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000; 114: 587-90.
8. Jones SK, Mackie RM, Hole DJ, et al. Further evidence of the safety of far in the management of psoriasis. Br J Dermatol 1985; 113: 97-101.
9. Larko O, Swanbeck G. Is UVB treatment of psoriasis safe? A study of extensively UVB-treated psoriasis patients compared with a matched control group. Acta Derm Venereol 1982; 62: 507-12.
10. Maughan WZ, Muller SA, Perry HO, et al. Incidence of skin cancers in patients with atopic dermatitis treated with ocal tar. A 25-year follow-up study. J Am Acad Dermatol 1980; 3: 612-5.
11. Pittelkow MR, Perry HO, Muller SA, et al. Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch Dermatol 1981; 117: 465-8.
12. Van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197: 31-6.
13. Van de Kerkhof PC, de Hoop D, de Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292-8.
14. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996; 135: 533-7.
15. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005; 19(Suppl 3): 2-6.
16. Pearce DJ, Stealey KH, Balkrishnan R, et al. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol 2006; 45: 370-4.
17. Feldman SR, Fleischer Jr. AB, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol 2000; 39: 41-4.
18. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 91-3.
19. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108-12.
20. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121: 252-8.
21. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-84.
22. Spuls PI, Tuut MK, van Everdingen JJ, et al. The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis'. Ned Tijdschr Geneeskd 2004; 148: 2121-5.
23. Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 2005; 44: 355-60.
24. Van de Kerkhof PC. The management of psoriasis. Neth J Med 1998; 52: 40-5.
25. Ellis CN, Hermann RC, Gorsulowsky DC, et al. Etretinate therapy reduces inpatient treatment of psoriasis. J Am Acad Dermatol 1987; 17: 787-91.
26. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332: 581-8.
27. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999; 41: S25-S28.
28. Darsow U, Lubbe J, Taieb A, et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005; 19: 286-95.
29. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol 2004; 50: 391-404.
30. De Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis. Ned Tijdschr Geneeskd 2005; 149: 1096-100.
31. Ring J, Barker J, Behrendt H, et al. Review of the potential photococarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005; 19: 663-71.
32. Enderlein E, Meller S, Rieker J, et al. Current aspects of the therapy with topical calcineurin inhibitors. Hautarzt 2005; 56: 937-41.
33. Arnold WP, Boelen RE, van de Kerkhof PC. Local treatment of dermatoses in pregnancy. Ned Tijdschr Geneeskd 1995; 139: 1170-3.